Donna Culton, MD, PhD, is professor of dermatology at the University of North Carolina at Chapel Hill

Donna Culton, MD, PhD

HCPLive Five: Maui Derm NP+PA Summer 2026

, held in Colorado Springs from June 24 to 27, brought together leading dermatologists to address diagnostic and treatment updates across numerous 

, including eczematous dermatitis, rosacea, autoimmune blistering disease, hair loss, and pigmentation disorders. From IL-13 inhibitor response as a patch testing gatekeeper to the expanding oral JAK inhibitor pipeline in vitiligo, this year's sessions reflected how targeted therapies are reshaping diagnostic sequencing across dermatology subspecialties.

 Nickel and ammonium persulfate are the most missed patch test allergens

 Ocular involvement in up to 50% of patients

 Suspect pemphigoid in patients > 65 years with treatment-resistant pruritus

 3 oral JAK inhibitors FDA-approved for severe alopecia areata

 Vitiligo affects up to 1% of population, half before age 20 years

rounds up 5 key takeaways NPs and PAs can apply in practice.

Eczematous Dermatitis: IL-13 Inhibitor Response Guides Patch Testing Decisions

Matthew Zirwas, MD, of Bexley Dermatology, discussed how IL-13 inhibitor response now guides patch testing decisions in eczematous dermatitis. He starts with a detailed history of product and exposure changes, then trials dupilumab or lebrikizumab across 6 weeks and 3 doses before considering patch testing. Nonresponse or worsening signals likely contact dermatitis warranting testing.

Zirwas identified nickel and ammonium persulfate as the 2 most missed allergens, noting dietary nickel can drive systemic contact dermatitis and ammonium persulfate exposure often stems from hot tub chemicals, both frequently excluded from standard patch testing.

Rosacea Staging: From Pediatric Erythema to Phymatous Disease

Hilary Baldwin, MD, from Atantla Health, used a single composite patient to trace rosacea from pediatric erythema through adult flushing, papulopustular disease, and late-stage phymatous and ocular involvement, matching treatment to each stage. Pediatric rosacea, affecting 4% or fewer children, is often missed because red cheeks appear benign. Background erythema responds to alpha agonists, flushing requires oral carvedilol or botulinum toxin, and telangiectasias need energy-based treatment. Papulopustular disease is the most treatable, with ivermectin, topical minocycline, and newer sub-antimicrobial oral options like Emrosi. Ocular rosacea responds to tetracyclines and topical ivermectin.

Pemphigus, Pemphigoid: Diagnosing Atypical Blistering Disease Presentations

Donna Culton, MD, PhD, of UNC School of Medicine, addressed atypical presentations of autoimmune blistering diseases. Pemphigus often presents with chronic oral ulcers rather than classic flaccid blisters, while pemphigoid may have a prodromal phase resembling urticaria or eczematous dermatitis. Culton advised suspecting non-bullous pemphigoid in patients > 65 years with pruritic disease unresponsive to first-line treatment. She cautioned that serology can be falsely negative, particularly in anti-p200 pemphigoid, and that perilesional biopsy is essential for direct immunofluorescence. Following dupilumab's 2025 FDA approval for bullous pemphigoid, NPs and PAs can initiate treatment earlier, reserving referral for treatment failure or diagnostic uncertainty.

Hair Loss Treatment: JAK Inhibitors and Oral Minoxidil Reshape Care

Benjamin Ungar, MD, of Mount Sinai's Alopecia Center of Excellence, called JAK inhibitors the biggest advance in hair loss treatment over the past 2 years, reshaping care for alopecia areata and scarring alopecia. 3 oral JAK inhibitors, baricitinib, ritlecitinib, and deuruxolitinib, are FDA-approved for severe AA, and Ungar's long-term data show no meaningful increase in cardiovascular or thromboembolic risk despite class-wide boxed warnings. He favors oral JAK inhibitors as first-line systemic therapy over traditional immunosuppressants. Low-dose oral minoxidil is increasingly used across hair loss subtypes, with hypertrichosis as the most common side effect. Ungar views nutraceuticals as adjunctive, useful mainly for patients with underlying nutrient deficiencies.

Vitiligo, Melasma: Pigmentation Treatment Pipeline Advances

George Martin, MD, of the Dermatology and Laser Center of Maui, reviewed advances in vitiligo and melasma treatment. Topical ruxolitinib remains the only FDA-approved topical vitiligo therapy, showing durable, increasing repigmentation through 2 to 3 years of treatment, though extensive disease above 50% body surface area requires additional systemic therapy. Oral JAK inhibitors, including povorcitinib, ritlecitinib, and upadacitinib, are advancing in additional late-stage trials and are expected to replace pulse-dose dexamethasone for widespread active disease.

For melasma, Martin emphasized combining lightening topicals with procedural treatment, noting current sunscreens inadequately block visible light despite its role in pigmentation.

Videos

5 dermatology takeaways from Maui Derm NP+PA Summer 2026, covering eczematous dermatitis, rosacea, blistering disease, hair loss, and pigmentation disorders.

When Blisters Don't Look Like Blisters: Diagnosing Pemphigus, Pemphigoid

 are among the most diagnostically challenging conditions in dermatology, and not just because they are rare. At 

in Colorado Springs, Donna Culton, MD, PhD, professor of dermatology and director of the Immunofluorescence Service at the University of North Carolina School of Medicine, led an interactive case-based session titled “Blistering Diseases: What's the Diagnosis?”

 The session addressed conditions that do not frequently present the way textbooks suggest they will.

Chronicity and Oral Involvement as Early Clues

For clinicians encountering a patient with suspected autoimmune blistering disease, Culton emphasized that the clinical picture is often more nuanced than the classic tense blister of bullous pemphigoid or the flaccid erosions of pemphigus vulgaris. Chronicity is a key historical feature, as is the distribution of involvement, particularly oral disease in pemphigus.

"For a pemphigus patient, a lot of times it's the chronicity of the disease, accompanying not only cutaneous features but also, and sometimes only, oral disease, so oral ulcers, sores, erosions, [and] bleeding,” Culton said. “That should tip you off to maybe this [being] pemphigus.”

For pemphigoid, the diagnostic challenge is somewhat different. Clinicians should be aware that many patients experience a prodromal phase that may resemble urticaria, eczematous dermatitis, or prurigo nodularis, none of which immediately suggest a blistering disease. For some patients, this non-bullous phenotype is not a prodrome at all. It is simply how their disease manifests.

While blisters and erosions are the classic hallmarks of autoimmune blistering diseases, lesions may present in highly variable forms, including erythematous, urticarial, prurigo-like, or eczematous manifestations.

 This heterogeneity is a primary reason these diagnoses are missed or delayed.

Culton offered a practical rule of thumb for NPs and PAs working in general dermatology: any patient > 65 years old presenting with a pruritic disorder that is not responding to topical steroids or other first-line treatment should prompt consideration of a non-bullous form of pemphigoid.

During the meeting, Culton presented 2 cases chosen specifically to illustrate atypical presentations. The first involved a younger-than-expected patient with pemphigus herpetiformis: a clinical variant with an annular morphology that does not resemble the flaccid blisters most clinicians associate with pemphigus.

"It just trips people up because they're not expecting pemphigus in a younger patient, and they're not expecting it to look more classic in the flaccid blisters," Culton said.

The diagnostic stakes here are high. Culton noted that data increasingly support earlier initiation of B cell depletion therapy in pemphigus, with earlier treatment correlating with better odds of achieving clinical remission. A delayed or missed diagnosis translates directly into a delayed start on rituximab and a worse long-term prognosis.

The second common pitfall she addressed involves serological testing. Indirect immunofluorescence and ELISA can return low-titer or negative results even in pathologically confirmed disease, particularly in atypical presentations. Newer forms of pemphigoid, including anti-p200 pemphigoid, do not produce antibodies to BP180 or BP230, the targets of standard ELISA panels. When the serology is negative but the clinical picture fits, Culton said that clinicians should not abandon the diagnosis.

For NPs and PAs considering how to work up a suspected case before or alongside referral, Culton underscored 2 practical prerequisites: knowing where to biopsy and having a reliable lab capable of processing specimens for direct immunofluorescence. Perilesional tissue, not the lesion itself, is the appropriate site for direct immunofluorescence biopsy, Culton explained.

Referral Thresholds and the Role of Dupilumab

For pemphigus, Culton recommended prompt specialist referral once a diagnosis is biopsy-confirmed, given that rituximab initiation typically requires specialist involvement and that earlier B cell depletion confers a durable benefit.

For pemphigoid, the treatment calculus has shifted considerably following the June 2025 FDA approval of dupilumab (Dupixent), the first targeted therapy to receive approval for bullous pemphigoid and the 8th indication for the biologic in diseases driven by type 2 inflammation.

 Because many NPs and PAs are already experienced prescribers of dupilumab, Culton suggested this approval creates an opportunity for earlier intervention without immediate specialist escalation. Referral becomes most pressing when a patient is failing dupilumab or when the diagnosis remains uncertain.

"A referral is more necessary if the patient is failing [dupilumab]," she said. "[That would be a reason] to prompt a referral to a specialist."

Editor’s note: Reported disclosures for Culton include GENZYME CORPORATION, ARGENX US, and Regeneron Pharmaceuticals.

Culton D. Blistering Diseases: What's the Diagnosis? – Interactive Format. Session presented at Maui Derm Summer 2026 in Colorado Springs on June 27.

van Beek N, Holtsche MM, Atefi I, et al. State-of-the-art diagnosis of autoimmune blistering diseases. 

https://doi.org/10.3389/fimmu.2024.1363032

Smith T. FDA Approves Dupilumab (Dupixent) for Bullous Pemphigoid in Adult Patients. 

 Published June 20, 2025. Accessed June 25, 2026. 

https://www.hcplive.com/view/fda-approves-dupilumab-dupixent-for-bullous-pemphigoid-in-adult-patients

Donna Culton, MD, PhD, explains why autoimmune blistering diseases often look nothing like the textbook and how to pursue the diagnosis anyway.

When Blisters Don't Look Like Blisters: Diagnosing Pemphigus, Pemphigoid 

Donna Culton, MD, PhD, spoke in an interview with 

2025 Fall Clinical Dermatology Conference

 in Las Vegas, highlighting notable takeaways from her portion of the session, ‘Bullous Pemphigoid: The Time to Treat is Now.’

. This talk, co-presented by Culton and Prince Adotma, MD, highlighted the emergence of non-bullous presentations, such as urticaria and eczematous eruptions, in over half of patients.

Treatment and Diagnosis Strategies for Bullous Pemphigoid, With Donna Culton, MD, PhD

“One of the newer concepts that we're realizing is, is this concept of non-bullous pemphigoid,” Culton said. “A lot of patients, we know, will start with a prodromal urticarial phase. But what we're realizing is, oftentimes, it's not just a prodrome, and sometimes it's more than just urticaria. So, for non-bullous pemphigoid, in over half of patients, the first presentation of their pemphigoid is not blisters. It can be urticaria. It can be an eczematous eruption. It can be prurigo nodularis-like lesions. Even itch in an elderly patient should really be tipping us off.”

About 20% of patients never go on to develop blisters, Culton noted, highlighting a study in which investigators’ follow-up interactions over 18 months demonstrated a lack of blisters in patients with the condition.

“We really need to be thinking about this condition in patients over 60, and certainly over 70, any new onset, pruritic eruption, and be thinking about pemphigoid,” Culton said. “So, you might ask, ‘Well, how do we make the diagnosis of pemphigoid, whether it be bullous or non-bullous?’ We all know that you do a biopsy for routine light microscopy, or for H and E, and that typically will show a subepidermal split with the eosinophils when the patient has blisters. But if they don't have blisters, it may not show that. In fact, it might just show eosinophilic spongiosis or examination eruption.”

In light of this, Culton noted the real way to confirm the diagnosis would be a biopsy with direct immunofluorescence.

“You remember that has to be perilesional, so not on the blister, and it should show IgG and C3 at the basement membrane zone,” Culton explained. “And that really is the key to making the diagnosis, because that would be positive whether the pemphigoid is presenting with blisters or without blisters.”

To find out more information about this topic and other points made in this interview, view Culton’s full video above.

The quotes included in this summary article were edited for clarity.

Culton previously reported the following disclosures: Argenx, Advisory board; iCell, Consultant; Sanofi Genzyme, Advisory board; Sitala, Consultant; Regeneron, Consultant and Investigator; Cabaletta, Investigator; Incyte, Investigator and Stockholder; and Lilly, Investigator.

Adotama P, Culton D. Seminar-in-Depth: Bullous Pemphigoid: The Time to Treat is Now. Session presentation at the 2025 Fall Clinical Dermatology Conference, Las Vegas, Nevada, Oct 23-26, 2025.

This Fall Clinical interview features a series of highlights from Culton’s portion of the session ‘Bullous Pemphigoid: The Time to Treat is Now.’

Donna Culton, MD, PhD

Articles